Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study.

Stewart JM, Srivastava SK, Fung AE, Mahmoud TH, Telander DG, Hariprasad SM, Ober MD, Mruthyunjaya P.

Ocul Immunol Inflamm. 2011 Feb;19(1):32-8. doi: 10.3109/09273948.2010.520405. Epub 2010 Oct 31.

PMID:
21034310
2.

Bacterial contamination of needles used for intravitreal injections: comparison between 27-gauge and 30-gauge needles.

Tufan HA, Vural A, Gencer B, Kara S, Arikan S, Yuksel E.

Ocul Immunol Inflamm. 2013 Oct;21(5):366-70. doi: 10.3109/09273948.2013.801988. Epub 2013 Jul 22.

PMID:
23875860
3.

Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections.

de Caro JJ, Ta CN, Ho HK, Cabael L, Hu N, Sanislo SR, Blumenkranz MS, Moshfeghi DM, Jack R, de Kaspar HM.

Retina. 2008 Jun;28(6):877-83. doi: 10.1097/IAE.0b013e31816b3180.

PMID:
18536606
4.

Bacterial contamination of needle points after intravitreal injection.

Nentwich M, Yactayo-Miranda Y, Weimann S, Froehlich S, Wolf A, Kampik A, Mino De Kaspar H.

Eur J Ophthalmol. 2009 Mar-Apr;19(2):268-72.

PMID:
19253245
5.

[Bacterial contamination of needles after intravitreal injection in Paraguay].

Gines JC, Nentwich MM, Peggy Bedoya AH, Cibils P, Esteche A, Laspina F, Samudio M, Fariña N, de Kaspar HM.

Ophthalmologe. 2012 Aug;109(8):782-7. doi: 10.1007/s00347-012-2591-2. German.

PMID:
22733287
6.

Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.

Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA; Post-Injection Endophthalmitis (PIE) Study Team..

Ophthalmology. 2011 Oct;118(10):2028-34. doi: 10.1016/j.ophtha.2011.02.034. Epub 2011 Jun 25.

PMID:
21705087
7.

Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.

Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, Hollands H, Sharma S.

Retina. 2008 Nov-Dec;28(10):1395-9. doi: 10.1097/IAE.0b013e3181884fd2.

PMID:
18827737
8.

Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.

Mason JO 3rd, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO, Yunker JJ, Vail RS.

Retina. 2008 Apr;28(4):564-7. doi: 10.1097/IAE.0b013e3181633fee.

PMID:
18398358
9.

Histopathology of streptococcus mitis/oralis endophthalmitis after intravitreal injection with bevacizumab: a report of 7 patients.

Matthews JL, Dubovy SR, Goldberg RA, Flynn HW Jr.

Ophthalmology. 2014 Mar;121(3):702-8. doi: 10.1016/j.ophtha.2013.10.015. Epub 2014 Jan 16.

PMID:
24439760
10.

Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.

Bhavsar AR, Googe JM Jr, Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, Glassman AR; Diabetic Retinopathy Clinical Research Network..

Arch Ophthalmol. 2009 Dec;127(12):1581-3. doi: 10.1001/archophthalmol.2009.304.

11.

Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).

Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ; Pan American Collaborative Retina Group (PACORES)..

Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):81-7. Epub 2007 Aug 3.

PMID:
17674014
12.

The article by Fintak et al on the incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.

El-Ashry MF, Dhillon B.

Retina. 2009 May;29(5):720-1; author reply 721-2. doi: 10.1097/IAE.0b013e3181a57fa5. No abstract available.

PMID:
19430287
13.

ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics.

Li AL, Wykoff CC, Wang R, Chen E, Benz MS, Fish RH, Wong TP, Major JC Jr, Brown DM, Schefler AC, Kim RY, OʼMalley RE.

Retina. 2016 Jul;36(7):1349-56. doi: 10.1097/IAE.0000000000000901.

PMID:
26655622
14.

A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections.

Moss JM, Sanislo SR, Ta CN.

Ophthalmology. 2009 Aug;116(8):1498-501. doi: 10.1016/j.ophtha.2009.02.024. Epub 2009 Jun 5.

PMID:
19501409
15.

Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.

Lima LH, Zweifel SA, Engelbert M, Sorenson JA, Slakter JS, Cooney MJ, Klancnik JM, Yannuzzi LA, Freund KB.

Retina. 2009 Oct;29(9):1213-7. doi: 10.1097/IAE.0b013e3181b32d27.

PMID:
19934815
16.

Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics.

Hsu J, Gerstenblith AT, Garg SJ, Vander JF.

Am J Ophthalmol. 2014 Mar;157(3):514-8.e1. doi: 10.1016/j.ajo.2013.10.003. Epub 2013 Oct 19.

PMID:
24332373
17.

Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.

Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.

Retina. 2007 Apr-May;27(4):432-8.

PMID:
17420694
18.

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.

Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU.

Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):941-8. Epub 2006 Dec 21.

PMID:
17186262
19.

Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.

Shimada H, Hattori T, Mori R, Nakashizuka H, Fujita K, Yuzawa M.

Graefes Arch Clin Exp Ophthalmol. 2013 Aug;251(8):1885-90. doi: 10.1007/s00417-013-2274-y. Epub 2013 Feb 7.

PMID:
23389553
20.

Bilateral simultaneous intravitreal injections in the office setting.

Bakri SJ, Risco M, Edwards AO, Pulido JS.

Am J Ophthalmol. 2009 Jul;148(1):66-9.e1. doi: 10.1016/j.ajo.2009.02.013. Epub 2009 Apr 29.

PMID:
19403114

Supplemental Content

Support Center